Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis update

Stroke

Volumn 43, Issue 10, 2012, Pages 2671-2676

  Vergouwen, Mervyn D I ^a   Algra, Ale ^a   Rinkel, Gabriel J E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

antagonist; cerebral infarction; delayed cerebral ischemia; endothelin receptor; outcome; subarachnoid hemorrhage; systematic review; vasospasm

Indexed keywords

BOSENTAN; CLAZOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; TAK 044;

ANEMIA; ARTERY DIAMETER; ARTICLE; BRAIN ANGIOGRAPHY; BRAIN INFARCTION; BRAIN VASOSPASM; COCHRANE LIBRARY; DIGITAL SUBTRACTION ANGIOGRAPHY; DRUG DOSE ESCALATION; DRUG EFFICACY; EFFECT SIZE; FOLLOW UP; GLASGOW OUTCOME SCALE; HUMAN; HYPOTENSION; LUNG EDEMA; MAXIMUM TOLERATED DOSE; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANKIN SCALE; RISK REDUCTION; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW;

DIOXANES; HUMANS; INCIDENCE; PEPTIDES, CYCLIC; PYRIDINES; PYRIMIDINES; RECEPTORS, ENDOTHELIN; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TETRAZOLES; TREATMENT OUTCOME; VASOSPASM, INTRACRANIAL;

EID: 84866736325     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.666693     Document Type: Article

References (19)

1. Vergouwen MD, Ilodigwe D, Macdonald RL. Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasmdependent and -independent effects. Stroke. 2011;42:924-929.
2. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials. Neurocrit Care. 2010;13:416-424.
3. Kramer A, Fletcher J. Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage?: a meta-analysis. Stroke. 2009;40:3403-3406.
4. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10:618-625.
5. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012; 43:1463-1469.
6. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org. Accessed May 2, 2012.
7. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480-484.
8. Shaw MD, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM. Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group. J Neurosurg. 2000;93:992-997. (Pubitemid 32800609)
9. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg. 2005; 103:9-17. (Pubitemid 43193928)
10. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39:3015-3021.
11. Vergouwen MD, Etminan N, Ilodigwe D, Macdonald RL. Lower incidence of cerebral infarction correlates with improved functional outcome after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2011;31:1545-1553.
12. Solenski NJ, Haley EC Jr., Kassell NF, Kongable G, Germanson T, Truskowski L, et al. Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. Crit Care Med. 1995;23:1007-1017.
13. Vergouwen MD, Fang J, Casaubon LK, Stamplecoski M, Robertson A, Kapral MK, et al. Higher incidence of in-hospital complications in patients with clipped versus coiled ruptured intracranial aneurysms. Stroke. 2011;42:3093-3098.
14. Diringer MN, Bleck TP, Claude Hemphill J III, Menon D, Shutter L, Vespa P, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15:211-240.
15. Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41:2391-2395.
16. Vergouwen MD, Vermeulen M, Coert BA, Stroes ES, Roos YB. Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab. 2008;28:1761-1770.
17. Etminan N, Vergouwen MD, Ilodigwe D, Macdonald RL. Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab. 2011; 31:1443-1451.
18. Dreier JP, Major S, Manning A, Woitzik J, Drenckhahn C, Steinbrink J, et al. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain. 2009;132:1866-1881.
19. Yundt KD, Grubb RL Jr., Diringer MN, Powers WJ. Autoregulatory vasodilation of parenchymal vessels is impaired during cerebral vasospasm. J Cereb Blood Flow Metab. 1998;18:419-424. (Pubitemid 28166517)